ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
0.00
0.00%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
0.00
0.00%
INO
6.96
-0.04
-0.57%
ISCO
1.04
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
-0.08
-2.66%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
0.00
0.00%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
0.00
0.00%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
0.00
0.00%
INO
6.96
-0.04
-0.57%
ISCO
1.04
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
-0.08
-2.66%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
0.00
0.00%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
Home » Archive by Category

Xconomy

As Iraqi Immigrant, Bio CEO Sees Pros and Cons in U.S. Travel Ban

February 5, 2017 – 9:01 pm

Noori Barka came to California on an H-1B visa in 1986 to work for Santa Monica-based Specialty Laboratories, a medical diagnostics company best known for its clinical testing services. Barka said he…

[[Click headline to continue reading.]]

Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins

February 3, 2017 – 6:10 am

Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life…

[[Click headline to continue reading.]]

Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing

February 2, 2017 – 12:09 pm

A team of decorated academic chemists in San Diego have been working since 2014 on a biotech startup that aims to find new drugs faster. The company now has a lot of cash in the bank and a well-known…

[[Click headline to continue reading.]]

Insurer UHC Will Cover Biogen Spine Drug, But With Limits And Proof

February 2, 2017 – 7:25 am

[Updated, 1:57 pm E.T., see below] Another major U.S. health insurer, UnitedHealthCare, has said it would cover the first-ever approved drug for the rare disease spinal muscular atrophy, a closely…

[[Click headline to continue reading.]]

Seed-Stage Deals Show Growing Diversity of Agtech Investments

February 1, 2017 – 11:59 am

Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though. A growing…

[[Click headline to continue reading.]]

Still No Official Word From Biopharma Groups About Trump Travel Ban

January 31, 2017 – 4:09 am

Four days after President Donald Trump issued an order to temporarily ban U.S. entry for people from seven Muslim-majority countries—and for all refugees—the drug industry’s two…

[[Click headline to continue reading.]]

Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More

January 27, 2017 – 5:55 am

It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender parity in public biotech boardrooms. Tensions continued to mount between…

[[Click headline to continue reading.]]

Jounce Gets $102M As Biotech IPOs Gain Steam in ’17

January 27, 2017 – 3:44 am

Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. The Cambridge, MA,…

[[Click headline to continue reading.]]

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

January 26, 2017 – 9:59 am

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. The San…

[[Click headline to continue reading.]]

Just Four Months After Series A, Delinia Sells to Celgene For $300M

January 26, 2017 – 5:35 am

It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of…

[[Click headline to continue reading.]]